Investing in the time of coronavirus: the good, the bad and the hopeful, as biotech VC firms close funds worth $3B
Apart from disrupting biopharma R&D and regulatory timelines, the coronavirus pandemic has inevitably ravaged financial markets and eroded investor risk appetite. Investing in the time of coronavirus feels reckless, but if biotech venture funds are any indication, the time is ripe.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,700+ biopharma pros reading Endpoints daily — and it's free.